For external and transdermal professional application only
Hogan, Associate Professor and Principal Investigator, at Lonsdale Human Health Institute in Maynooth University, discussed the findings: "My team and I are very excited by these new findings in relation to the effects of the GLP-1 treatment on people with obesity, and it appears to result in real, tangible benefits for those currently on the drug
Bonus tip: Pair turmeric with black pepper to help your body absorb it better
9 Iran Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran Correspondence: Fatemeh Farjadian Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, P.o
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with specific FDA-approved indications: Ozempic and Rybelsus for type 2 diabetes management, and Wegovy specifically for chronic weight management in adults with BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity
